Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 45  |  Issue : 2  |  Page : 57-62

Profile of human epidermal growth factor receptor 2 expression in epithelial ovarian carcinomas: A multicenter study from Southeast Nigeria


1 Department of Histopathology, Nnamdi Azikiwe University Teaching Hospital, Anambra State, Nigeria
2 Department of Anatomy, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria
3 Department of Histopathology, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria

Correspondence Address:
Chinedu Onwuka Ndukwe
Department of Histopathology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jss.JSS_36_18

Rights and Permissions

Background: Human epidermal growth factor receptor 2 (HER2/neu) in epithelial ovarian cancers (EOCs) has been proposed in targeted oncological therapy as a way forward in the treatment of ovarian cancer. Currently, there is a paucity of data on the expression of HER2 in EOC in Nigeria. Objective: This study, therefore, aims to carry out an immunohistochemical study of histologically diagnosed EOC in Nnewi, Southeast Nigeria. Materials and Methods: The hematoxylin and eosin slides and formalin-fixed-paraffin-embedded tissue blocks of histologically diagnosed cases of epithelial ovarian carcinomas in the two histopathology laboratories in Nnewi, Anambra state, over a 12-year period were retrieved from the archives. Archival formalin-fixed-paraffin-embedded tissue blocks of histologically normal ovaries in these laboratories were also retrieved to serve as controls. Sections were made from the tissue blocks and stained with HER2 immunostain. Results: Fifty EOC specimens and 20 histologically normal ovaries were stained with HER2 immunostain. There was statistically significant difference in HER2 expression between normal ovaries and EOC (P = 0.016). HER2/neu- positive staining was not observed in the histologically normal ovaries. However, nine (18%) of the EOC showed HER2/neu- positive staining. HER2 positivity within EOC was independent of age (P = 0.134), tumor grade (P = 0.141), histological subtyping (P = 0.080), and molecular subtyping (P = 0.168). However, there was more HER2 positivity among those older than 50 years, low-grade carcinomas, mucinous EOC, and Type 1 EOC. Conclusion: Overall, these data support the dualistic model of ovarian carcinogenesis in Nigerian patients and therefore recommend further studies to determine the efficacy of anti-HER2/neu monoclonal antibodies in the treatment of EOC in these patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed793    
    Printed123    
    Emailed0    
    PDF Downloaded127    
    Comments [Add]    

Recommend this journal